IFNAR1 and systemic lupus erythematosus: As type I IFNs are major drivers of SLE pathogenesis, it would be intriguing to understand if targeting that pathway by IFNAR blockade or JAK inhibition could potentially influence the metabolic reprogramming of haematopoietic and other immune cells.